{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000611","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.254501+00:00","generated_at":"2026-06-16T08:22:50.646838+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Immunic appoints MS expert Dr. Richard Rudick to Board; Dr. Ossipow to retire at 2023 meeting","bullets":["Dr. Rudick appointed as Class III director effective April 26, 2023; term ends at 2023 Annual Meeting.","Received option to purchase 32,000 shares, vesting monthly over three years, exercise price at grant date closing price.","Dr. Vincent Ossipow will not stand for re-election at 2023 Annual Meeting, continues until then; no disagreement cited.","Board size increased from 7 to 8 directors upon Rudick's appointment.","Rudick brings 35+ years of MS expertise from Cleveland Clinic and Biogen, expected to support vidofludimus calcium development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000611","json":"https://secwatch.observer/filing/0001193805-23-000611.json","markdown":"https://secwatch.observer/filing/0001193805-23-000611.md","text":"https://secwatch.observer/filing/0001193805-23-000611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/0001193805-23-000611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/e618552_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:22:50.646838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a3d287040","claim":"Dr. Vincent Ossipow departed as Director at IMMUNIC, INC..","evidence_excerpt":"Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/0001193805-23-000611-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"plans to retire"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b58cec0cf7","claim":"Dr. Richard Rudick was appointed as Director at IMMUNIC, INC..","evidence_excerpt":"On April 27, 2023, Immunic, Inc. (the “Company”) announced the appointment of Dr. Richard Rudick as a member of the Board of Directors (the “Board”) of the Company, effective as of April 26, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/0001193805-23-000611-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}